Table 3.
Multivariable Logistic Regression Analysis to Determine the Effectiveness of Molnupiravir
| Explanatory Variable | Odds Ratio | 95% CI | P Value |
|---|---|---|---|
| Model 1a | |||
| Treatment | |||
| Nonrecipients | 1.00 | … | … |
| Molnupiravir recipients | 0.40 | .32–.48 | <.001 |
| Age, per year | 1.06 | 1.04–1.07 | <.001 |
| Previous COVID-19 | |||
| No previous SARS-CoV-2 infection | 1.00 | … | … |
| Previous SARS-CoV-2 infection | 0.45 | .19–.92 | .05 |
| Vaccination status | |||
| Unvaccinated | 1.00 | … | … |
| Vaccination: 2, 3, or 4 doses ≤6 mo before index SARS-CoV-2 infection | 0.36 | .30–.45 | <.001 |
| Vaccination: 2, 3, or 4 doses >6 mo before index SARS-CoV-2 infection | 1.08 | .63–1.76 | .772 |
| Model 2b | |||
| Treatment | |||
| Nonrecipients | 1.00 | … | … |
| Molnupiravir recipients | 0. 31 | .22–.43 | <.001 |
| Age, per year | 1.11 | 1.09–1.14 | <.001 |
| Previous COVID-19 | |||
| No previous SARS-CoV-2 infection | 1.00 | … | … |
| Previous SARS-CoV-2 infection | 0.56 | .13–1.57 | .34 |
| Vaccination status | |||
| Unvaccinated | 1.00 | … | … |
| Vaccination: 2, 3, or 4 doses ≤6 mo before index SARS-CoV-2 infection | 0.36 | .26–.49 | <.001 |
| Vaccination: 2, 3, or 4 doses >6 mo before index SARS-CoV-2 infection | 1.22 | .55–2.45 | .60 |
Abbreviation: ICU, intensive care unit.
aModel 1: hospitalization without ICU admission, clinical deterioration, or death vs no hospitalization, ICU admission, clinical deterioration, or death.
bModel 2: death with or without ICU admission or clinical deterioration vs no hospitalization, ICU admission, clinical deterioration, or death.